Effects of apalutamide dose reduction on skin‐related adverse events in patients with advanced prostate cancer: A multicenter retrospective study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of apalutamide dose reduction on skin‐related adverse events in patients with advanced prostate cancer: A multicenter retrospective study
Authors
Keywords
-
Journal
PROSTATE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-10-31
DOI
10.1002/pros.24453
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy of combined androgen blockade therapy in patients with metastatic hormone‐sensitive prostate cancer stratified by tumor burden
- (2022) Yoshiyuki Nagumo et al. INTERNATIONAL JOURNAL OF UROLOGY
- Effect of upfront combination therapy on the overall survival of patients with metastatic castration‐sensitive prostate cancer: A multicenter retrospective study
- (2022) Toshikazu Tanaka et al. INTERNATIONAL JOURNAL OF UROLOGY
- Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events
- (2022) MICHIE KATSUTA et al. ANTICANCER RESEARCH
- Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study
- (2022) Huybrecht T’jollyn et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Impact of body size on skin‐related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study
- (2022) Daichi Sasaki et al. INTERNATIONAL JOURNAL OF UROLOGY
- Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
- (2022) Hirotsugu Uemura et al. INTERNATIONAL JOURNAL OF UROLOGY
- Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium
- (2022) Yoichiro Tohi et al. International Journal of Clinical Oncology
- Treatment strategies and outcomes in a long‐term registry study of patients with high‐risk metastatic hormone‐naïve prostate cancer in Japan: An interim analysis of the J‐ROCK study
- (2022) Hirotsugu Uemura et al. INTERNATIONAL JOURNAL OF UROLOGY
- Predictive factors of survival outcomes in first‐line therapy for metastatic castration‐resistant prostate cancer
- (2021) Masaki Shiota et al. INTERNATIONAL JOURNAL OF UROLOGY
- Useful predictors of progression‐free survival for Japanese patients with LATITUDE‐high‐risk metastatic castration‐sensitive prostate cancer who received upfront abiraterone acetate
- (2021) Kiyoshi Takahara et al. INTERNATIONAL JOURNAL OF UROLOGY
- Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
- (2020) Hiroji Uemura et al. Prostate International
- Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
- (2020) Hiroji Uemura et al. BMC Urology
- Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study
- (2020) Hirotsugu Uemura et al. INTERNATIONAL JOURNAL OF UROLOGY
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidemiology of prostate cancer in Asian countries
- (2018) Takahiro Kimura et al. INTERNATIONAL JOURNAL OF UROLOGY
- Clinical and molecular features of treatment-related neuroendocrine prostate cancer
- (2018) Shusuke Akamatsu et al. INTERNATIONAL JOURNAL OF UROLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- (2018) Christos E. Kyriakopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer
- (2018) Masaki Shiota et al. INTERNATIONAL JOURNAL OF UROLOGY
- Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition)
- (2017) Yoshiyuki Kakehi et al. INTERNATIONAL JOURNAL OF UROLOGY
- Current treatment strategies for advanced prostate cancer
- (2017) Kazumasa Komura et al. INTERNATIONAL JOURNAL OF UROLOGY
- Recent Trends in PSA Testing and Prostate Cancer Incidence
- (2016) Ruth Etzioni et al. JAMA Oncology
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started